Tokyo Kikai shareholders approve poison pill, setting up court battle

Tajammul Pangarkar
Tajammul Pangarkar

Updated · Oct 23, 2021

SHARE: is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
Advertiser Disclosure

At Scoop, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Scoop. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

October 23, 2021

By Makiko Yamazaki

TOKYO (Reuters) – Shareholders in Tokyo Kikai Seisakusho Ltd approved a “poison pill” measure on Friday aimed at blocking a takeover attempt by its top investor, setting up a court battle that will have sweeping implications for hostile bids in Japan.

Tokyo Kikai, a little known company that is the country’s largest maker of newspaper printing presses, said a majority of its shareholders approved a measure that would dilute Asia Development Capital’s (ADC) 40% stake.

ADC was excluded from the vote and has already sought an injunction to nullify it. Had investors voted on Friday against the poison pill it would have handed ADC a victory.

About 79% of the votes supported the poison pill, Tokyo Kikai said in a statement. ADC said Tokyo Kikai would have lost if ADC had not been excluded, as the number of votes cast for the poison pill were fewer than those ADC could have cast alone.

Now, focus will turn to the injunction and the Tokyo District Court ruling expected next week that will be the first to examine an attempt to exclude an investor from a shareholder vote on a poison pill.

A victory for Tokyo Kikai would potentially make it easier for other Japanese companies to use poison pills.

Tokyo Kikai has said ADC hurts its corporate value, while the fund argues that a ruling in Tokyo Kikai’s favour would fly in the face of shareholder equality.

The battle highlights both a rise in hostile takeovers in Japan over the past few years and what some experts see as inadequate takeover rules that leave companies, especially small ones, with few defences against hostile bids.

(Reporting by Makiko Yamazaki Editing by Edmund Blair, Mark Potter and Himani Sarkar)

Source Link Tokyo Kikai shareholders approve poison pill, setting up court battle

Tajammul Pangarkar

Tajammul Pangarkar

Tajammul Pangarkar is a CMO at Prudour Pvt Ltd. Tajammul longstanding experience in the fields of mobile technology and industry research is often reflected in his insightful body of work. His interest lies in understanding tech trends, dissecting mobile applications, and raising general awareness of technical know-how. He frequently contributes to numerous industry-specific magazines and forums. When he’s not ruminating about various happenings in the tech world, he can usually be found indulging in his next favorite interest - table tennis.